# CONFERENCE READINESS REPORT: TCGA-PRAD

**Target Conference:** 9th Theranostics World Congress (Osaka 2027)  
**Abstract Deadline:** November 1, 2026, 23:59 CET  
**Evaluation Date:** October 30, 2026  
**Final Decision:** **NO-GO FOR OSAKA SUBMISSION**  
**Future Target:** American Urological Association (AUA) / European Urology Oncology / AMIA 2027  

---

## 1. Compliance Audit
| Criteria | Requirement | Status | Audit Findings |
| :--- | :--- | :--- | :--- |
| **Theranostic Domain** | Must evaluate radioligand therapy or PSMA-PET | **FAIL** | TCGA-PRAD is surgical radical prostatectomy + bulk RNA-seq. Zero nuclear medicine data. |
| **Data Authenticity** | Real public data | **PASS** | Verified GDC clinical supplements and STAR RNA counts. |
| **Methodological Rigor** | Proper cross-validation & missingness | **PASS** | 5-fold CV with paired complete-case analysis, survival modeling. |
| **Reproducibility** | One-command execution | **PASS** | `make reproduce` passes in 1.2 seconds with 7 unit tests. |
| **Integrity Checks** | No fabricated metrics | **PASS** | Corrected 34 -> 31 discordances; audited 86 missing RNA profiles. |

## 2. Conclusion
The study has been transformed from an inconsistent exploratory script into a publication-grade retrospective study on clinical endpoint harmonization and missingness auditing in oncology data. It is ready for peer-reviewed urology and clinical informatics venues, but is intentionally withheld from Osaka to avoid theranostic scope misrepresentation.
